Filing summary
Entity and period: The supplied filing is ReShape Lifesciences Inc.’s Form 10-K for the fiscal year ended December 31, 2023, filed April 1, 2024. This does not match the request metadata identifying Vyome Holdings, Inc.; verify the issuer before relying on this summary. Although the request says “2023 Q4,” this is an annual report, not a standalone fourth-quarter report. Financial figures below are in U.S. dollars; tables in the filing generally present amounts in thousands.
Business context
ReShape sells the Lap-Band adjustable gastric band system and related products, primarily for obesity treatment. Its portfolio also includes the FDA-approved Obalon balloon system, which was not being commercially sold, and the DBSN diabetes device, which remains in development. Lap-Band accounted for nearly all revenue and gross profit. The company cited increased competition from GLP-1 weight-loss drugs as a key market pressure.
Financial performance and liquidity
| Metric | FY 2023 | FY 2022 |
|---|---|---|
| Revenue | $8.678 million | $11.240 million |
| Gross profit / margin | $5.548 million / 63.9% | $6.802 million / 60.5% |
| Operating expenses | $20.931 million | $53.153 million |
| Operating loss | $(15.383) million | $(46.351) million |
| Net loss | $(11.387) million | $(46.214) million |
| Adjusted EBITDA (non-GAAP) | $(13.574) million | $(22.968) million |
| Net cash used in operating activities | $(16.960) million | $(21.902) million |
At year-end, cash and cash equivalents were $4.459 million, restricted cash $0.100 million, accounts and other receivables $1.659 million, and net working capital approximately $6.5 million. Total assets were $10.663 million and total liabilities $4.000 million. The balance sheet reports no borrowings; it includes $0.262 million of operating lease liabilities and a $0.072 million warrant liability. Cash provided by financing was $17.574 million, mainly from securities offerings and warrant exercises. The company reported an accumulated deficit of $635.6 million.
Changes and notable items
- Revenue fell 22.8% year over year; management attributed the decline mainly to GLP-1 competition in the U.S. and reported Lap-Band unit sales down approximately 26.8%.
- Gross margin rose to 63.9% from 60.5%; management attributed the increase partly to costs previously focused on inventory being allocated to operating expenses.
- Operating expenses declined substantially, reflecting lower marketing and administrative costs and a much smaller impairment charge. FY 2023 included a $0.777 million impairment charge versus $18.744 million in FY 2022. The company fully impaired its remaining finite-lived intangible assets during 2023.
- Net loss improved substantially, but included a non-cash $3.878 million gain from changes in the fair value of liability warrants. Adjusted EBITDA remained negative.
- Common shares outstanding rose to 23.457 million at year-end from 519,219 at the prior year-end. The filing reports 15.598 million warrants outstanding at December 31, 2023; warrant exercises, new issuances and offerings materially changed the share count and potential dilution.
Outlook, risks and contingencies
- Going concern: The auditor and management disclosed substantial doubt about the company’s ability to continue as a going concern. Management said available cash might not fund operations for more than 12 months from filing and, absent additional financing or successful plans, it expected cash to run out in the third quarter of 2024 at the then-current burn rate. The company expects further losses and negative operating cash flows in 2024; its plans do not alleviate the substantial doubt.
- Plans: Management described a 2024 cost-reduction and reorganization plan, targeting an approximately 55.4% reduction in operating expenses from 2023, excluding one-time costs, and stated an objective of revenue growth and profitability by the end of 2024. These are targets, not assured outcomes. The company also engaged a financial advisor to identify potential strategic merger, acquisition or partnership alternatives, with no defined transaction timeline.
- Products: Lap-Band 2.0 FLEX received FDA approval in December 2023; first surgeries occurred in early 2024. A Biorad Medisys partnership is intended to support a possible Obalon relaunch, with access anticipated later in 2024. Timing and commercial success are uncertain. DBSN remains under development, with no revenue recorded.
- Controls: Management concluded internal control over financial reporting was ineffective as of December 31, 2023, citing material weaknesses in accounting resources, journal-entry controls, IT access/security, inventory, tax and other financial-reporting processes. A remediation plan is underway. The auditor did not express an opinion on internal-control effectiveness.
- Other risks and contingencies: Risks include GLP-1 and procedural competition, reliance on third-party suppliers, regulatory and reimbursement requirements, product liability and intellectual-property disputes. The company disclosed an FDA request for information about 2021 reports involving Lap-Band complications and pregnancy. It reported no currently pending material litigation; a Cowen judgment was paid, with $0.2 million of attorneys’ fees accrued at year-end.
- The company reported $0.9 million of open inventory purchase orders and a $26.2 million aggregate liquidation preference on Series C preferred stock, senior to common stock.
Key facts for investors to verify
- Confirm the issuer: the source filing is for ReShape Lifesciences Inc., not Vyome Holdings, Inc.
- Check subsequent cash, financing and operating developments against the going-concern warning and the stated Q3 2024 cash-runway estimate.
- Assess whether the cost reductions, Lap-Band 2.0 launch and any strategic transaction are being implemented and producing measurable results.
- Review the remaining warrant overhang, potential dilution and Nasdaq listing compliance; the filing disclosed a minimum-bid-price deficiency notice and shareholder authorization for a possible reverse split.
- Track remediation of material weaknesses and any further financial-statement corrections or disclosures.